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Bile acids destabilise HIF-1α and promote
anti-tumour phenotypes in cancer cell
models
J. P. Phelan1, F. J. Reen1, N. Dunphy1, R. O’Connor2 and F. O’Gara1,3*
Abstract
Background: The role of the microbiome has become synonymous with human health and disease. Bile acids, as
essential components of the microbiome, have gained sustained credibility as potential modulators of cancer progression
in several disease models. At physiological concentrations, bile acids appear to influence cancer phenotypes, although
conflicting data surrounds their precise physiological mechanism of action. Previously, we demonstrated bile acids
destabilised the HIF-1α subunit of the Hypoxic-Inducible Factor-1 (HIF-1) transcription factor. HIF-1 overexpression is an
early biomarker of tumour metastasis and is associated with tumour resistance to conventional therapies, and poor
prognosis in a range of different cancers.
Methods: Here we investigated the effects of bile acids on the cancer growth and migratory potential of cell lines where
HIF-1α is known to be active under hypoxic conditions. HIF-1α status was investigated in A-549 lung, DU-145 prostate
and MCF-7 breast cancer cell lines exposed to bile acids (CDCA and DCA). Cell adhesion, invasion, migration was assessed
in DU-145 cells while clonogenic growth was assessed in all cell lines.
Results: Intracellular HIF-1α was destabilised in the presence of bile acids in all cell lines tested. Bile acids were not
cytotoxic but exhibited greatly reduced clonogenic potential in two out of three cell lines. In the migratory prostate
cancer cell line DU-145, bile acids impaired cell adhesion, migration and invasion. CDCA and DCA destabilised HIF-1α in
all cells and significantly suppressed key cancer progression associated phenotypes; clonogenic growth, invasion and
migration in DU-145 cells.
Conclusions: These findings suggest previously unobserved roles for bile acids as physiologically relevant molecules
targeting hypoxic tumour progression.
Keywords: Bile acids, HIF-1 transcription factor, HIF-1α subunit, Cancer models, Hypoxia, Dimethyloxaloglycine (DMOG)
Background
The generation of intratumoral hypoxia (oxygen limitation)
is a steadfast predictor of tumour fate in cancer progression
and metastasis. Hypoxic cells acquire intrinsic molecu-
lar characteristics leading to therapy resistance and
aggressiveness [1]. Prevalent in many cancers, (e.g.
breast, cervix, ovary, prostate and the uterus), hypoxic
micro-environments are associated with oxygen mediated
molecular complexity, dynamic vascular alterations and
increased mortality rates [2, 3]. The molecular challenges
are therefore complex; the identification of hypoxic trig-
gers and the development and exploration of innovative
strategies to combat the aggressive hypoxic environment.
Recently, several studies have suggested that bile acids
(BAs) and synthetic bile acid derivatives, at physiological
concentrations, exhibit inhibitory effects on the in vitro
cellular development and progression of several cancers
including, prostate cancer [4], gastric carcinoma [5] and
colon cancer [6]. BAs control cholesterol homeostasis,
and have been likened to central signalling molecules
relaying ingestion and energy availability messages to
peripheral tissues [7, 8]. Found in the liver, primary BAs
(cholic acid (CA), chenodeoxycholic acid (CDCA) are
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synthesised from cholesterol [9]. These molecules are
metabolised by bacteria in the gastrointestinal (GI) tract
producing secondary BAs (deoxycholic acid (DCA) and
lithocholic acid (LCA). BAs are extensively recycled
(~95 %) via the enterohepatic circulation (EHC) to
maintain BA equilibrium in the gut [7].
Dysregulation of BA metabolism by infection, diet, stress
or inflammation leads to dysbiosis, which is associated with
several debilitating disease conditions such as Crohn’s
disease (CD), Coeliac disease, Inflammatory Bowel Disease
(IBD), atherosclerosis, hypercholesterolemia and gastro-
intestinal (GI) disease [7, 10]. While diet and genetics play
roles in dysregulation and perturbations, and gut microflora
composition is important for disease transition, there is
growing evidence that BAs are implicated in cancer
progression. Several studies have demonstrated the anti-
proliferative and anti-invasive effects of BAs in different
cancer cell models [4–6]. Not limited to phenotypic charac-
terisation, molecular evidence suggests that the nuclear bile
acid receptor, FXRα and the membrane bound G-protein
coupled receptor TGR5 play significant roles in linking BAs
and digestion to cancer progression [8]. These studies
suggest hitherto unexplored links between the microbiome,
the diet and cancer aetiology [11, 12].
HIF-1 (full length protein comprising HIF-1α and
HIF-1β subunits) is a master transcriptional regulator
implicated in several cancers, where overexpression
during hypoxia is associated with tumour aggression,
invasiveness, and resistance to conventional therapies in
cervical, breast, oligodendroglioma, oropharyngeal, ovar-
ian, endometrial cancer and gastro-intestinal stromal
tumours of the stomach [2, 13–15]. Targeting HIF-1α
(HIF-1 subunit) activity in a systematic and strategic man-
ner is essential if tumour based angiogenic, glycolytic, and
intra-tumour cell functions are to be inhibited. Similarly,
the blocking of HIF-1α related functions within the
tumour microenvironment using innovative molecular
therapies means new combinatorial approaches can be
adopted, incorporating existing chemo- and radiotherapy
regimens [16].
In previous work, we demonstrated BAs destabilised
HIF-1α not only in IB3-1 and S9 lung epithelial cells,
but also in the adenocarcinoma human alveolar basal
epithelial cell line (A-549) [17]. This led us to hypothe-
sise that BA mediated HIF-1α destabilisation may occur
in other cancer cell lines. Here we tested this in A-549,
MCF-7 and DU-145 cells and further tested the effects
on a range of cancer phenotypes.
Methods
Cell lines and maintenance
Cell lines were acquired from the American Tissue
Culture Collection (ATCC) (LGC Standards, Middlesex,
UK). Human prostate carcinoma cells, DU-145 (ATCC-
HTB-81), human lung adenocarcinoma cells, A-549
(ATCC-CCL-185) and human mammary epithelial
adenocarcinoma cells, MCF-7 (ATCC-HTB-22) were
maintained in basic Dulbecco’s modified Eagle’s medium
(Gibco-BRL, Paisley, UK) supplemented with 10 % foetal
calf serum (FCS) and 1 % (vol/vol) Penicillin/Strepto-
mycin (both from Sigma, Ireland) (complete medium).
Depending on cell type, supplements were added
according to ATCC instructions. Cells were maintained
in 5 % CO2 in a humidified atmosphere at 37 °C and
were routinely seeded into T75 tissue culture flasks
(Sarstedt, Ireland) and grown to a maximum of 80–
90 % confluence. At seeding and prior to experiments,
cells were washed in Phosphate Buffered Saline pH 7.4
(PBS) to remove cellular debris and dead cells. Cells were
detached using 0.5 % Trypsin-EDTA (Sigma-Aldrich) for
5 min, counted on the Countess Cell Counter (Life Tech-
nologies, Paisley, UK). Passage numbers did not exceed 25.
For all experiments (except untreated cells), cells were
supplemented with 200 μm dimethyloxaloglycine (DMOG).
Bile acid preparation
Dihydroxylated bile acids, DCA and CDCA (Sigma) were
solubilised in sterile distilled water to a concentration of
50 mM. For all procedures, a final concentration of
100 μM in complete medium was used.
HIF-1α immunofluorescence
The intracellular HIF-1α staining of cells grown on cov-
erslips in 6 well plates was carried out using the mouse
monoclonal antibody for the HIF-1α subunit (Abcam
ab16066). Cells were fixed with 4 % formaldehyde in
PBS pH 7.4 and incubated with a 1:20 dilution of the
monoclonal antibody overnight at 4 °C. The next day,
cells were washed with PBS and incubated with a
DyLight-488 conjugated secondary antibody. All images
were captured on a Zeiss LSM5 using the Zeiss HBO-
100 microscope illuminating system. Images were proc-
essed using the Zen AIM application imaging program
and converted to JPGs using Axiovision 40 Ver. 4.6.3.0.
At least three biological repetitions were carried out.
HIF-1α subunit ELISA
Cells were seeded onto 6 well plates in complete
medium and incubated in 5 % CO2 in a humidified at-
mosphere at 37 °C for 1–2 days. BAs were added in
fresh medium and cells re-cultured for a further 24 h.
After this period, cells were scraped into 500 μl chilled
PBS. Intracellular HIF-1α activity was assayed using the
HIF-1α subunit Human SimpleStep ELISA kit (Abcam)
according to manufacturer’s instructions with plates
assayed on a 96-well plate reader at 450 nm.
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Cytotoxicity
Lactate dehydrogenase (LDH) release was assayed as a
measure of cytotoxicity using an LDH colorimetric kit
(Roche) according to manufacturers’ instructions. Briefly,
cells were seeded onto 96 well plates and treated with
0.1 % Triton X-100 (control) or 100 μM BAs. Following a
16 h incubation at 37 °C and 5 % CO2, supernatants were
removed and added to catalyst reaction mixture in a fresh
plate and further incubated at 37 °C and 5 % CO2 for
30 min to allow for colour development which was quan-
tified on a spectrophotometer plate reader at 490 nm.
Cytotoxicity was expressed as a percentage of cells treated
with 0.1 % Triton (100 % cytotoxicity). All assays were car-
ried out in triplicate.
Phase contrast microscopy
Cells were seeded into 6 well plates on sterile coverslips
(Sarstedt) and treated as above for 16 h at 37 °C and 5 %
CO2. Coverslips were removed and fixed with 4 % para-
formaldehyde for 15 min, washed and stained with 0.1 %
crystal violet (Sigma) for 15 min followed by rinsing in
water several times and allowing the coverslips to dry.
Once dry, coverslips were viewed on a BX21 Olympus
microscope and images collected using the Cell’B pro-
gram and processed using Adobe Photoshop.
Annexin V apoptosis assay
Assays were carried out according to manufacturers’
(Invitrogen, UK) instructions. Briefly, cells were grown
on coverslips in 6 well plates for 1–2 days under experi-
mental conditions. Cinnabinaric acid (positive control)
was added to cells at a final concentration of 150 μm.
Cold PBS pH 7.4 was added to wells to wash away deb-
ris, after which Annexin V binding buffer was added to
wash cells (10 mM HEPES, 140 mM NaCl, 2.5 mM
CaCl2 pH 7.4). 15 μl Annexin V conjugate was added
per 100 μl Annexin binding buffer along with 0.1 μM
4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI)
for nucleus visualisation. Cells were incubated for
15 min at room temperature after which coverslips were
mounted on glass slides and viewed. All images were
captured on a Zeiss LSM5 using the Zeiss HBO-100
microscope illuminating system. Images were processed
using the Zen AIM application imaging program and
converted to JPGs using Axiovision 40 Ver. 4.6.3.0. At
least three biological repetitions were carried out.
Cell adhesion
96 well plates (Sarstedt) were coated with either 15 μg/
ml collagen (Sigma) or Matrigel 120 μg/ml (Corning)
and stored at 4 °C until required. On the day of assay,
plates were equilibrated in at 5 % CO2 in a humidified
atmosphere at 37 °C for 2 h prior to use. Newly passage
cells in 100 μl aliquots were seeded onto plates in the
presence or absence of BAs and left for 24 h at 5 % CO2
in a humidified atmosphere at 37 °C hours to adhere.
Matrix free wells acted as controls. Following adhesion,
cells were washed with PBS × 3 and fixed with 100 μl
methanol at −20 °C for 5 min. Once removed, cells were
stained for 15 min with 0.1 % crystal violet after which
they were rinsed with tap water. Following 10 min air-
drying, 50 μl of 0.5 % Triton X-100 was added to wells
and left overnight at room temperature with gentle agi-
tation. Plates were assayed on a plate reader at 590 nm.
All assays were carried out in triplicate.
Cell invasion
Twenty-four-well inserts with an 8 μm pore size poly-
ethylene terephthalate membranes (Corning) were
used to assess cell migration of cells using the extra-
cellular matrix, Matrigel (120 μg/ml) which was pipet-
ted onto the membrane. Once set, transwells were
either stored at 4 °C until required or equilibrated for
2 h with media in 5 % CO2 in a humidified atmos-
phere at 37 °C prior to use. The lower chambers were
filled with complete media acting as a chemoattract-
ant. Cells were seeded in each transwell and allowed
to migrate over a 24 h period in 5 % CO2 in a
humidified atmosphere at 37 °C. Cells were fixed by
replacing culture medium at the top and bottom of
the transwell with 4 % formaldehyde in PBS pH 7.4
for 15 min. Once fixed, transwells were washed in
PBS, stained with 0.2 % crystal violet for 10 min and
washed several times in distilled water. Non-migrated
cells were wiped from the transwell top using cotton
buds leaving only migrated cells at the bottom of the
membrane. These cells were counted using a stereo-
microscope and plotted as the percentage of invading
cells of the total number of plated cells. All assays
were carried out in triplicate.
Transwell migration
Twenty-four-well inserts with an 8 μm pore size poly-
ethylene terephthalate membranes (Corning) were used
to assess cell migration of cells. The lower chambers
were filled with complete media acting as a chemo-
attractant. Cells were seeded into each transwell insert
and allowed to migrate over a 24 h period in 5 % CO2 in
a humidified atmosphere at 37 °C. Cells were fixed by
replacing culture media at the top and bottom of the
transwell with 4 % formaldehyde in PBS pH 7.4 for
15 min. Once fixed, transwells were washed in PBS,
stained with 0.2 % crystal violet for 10 min and washed
several times in distilled water. Non migrated cells were
carefully wiped away from the top of the transwell using
cotton buds leaving only migrated cells at the bottom of
the membrane. These cells were counted using a stereo-
microscope and plotted as the percentage of invading
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cells of the total number of plated cells. All assays were
carried out in triplicate.
Clonogenic assay
Cells, seeded in 6 well plates at low density in complete
medium, were incubated with BAs for a period of 1–
3 weeks in 5 % CO2 in a humidified atmosphere at 37 °C.
Plates were left undisturbed for this period. After 3 weeks,
medium was removed and cells rinsed with PBS. Next,
cells were incubated in 4 % formaldehyde in PBS pH 7.4
for 20 min after which they were rinsed in PBS and incu-
bated with 0.5 % crystal violet (Sigma, Ireland) for 2 h at
room temperature. Wells were rinsed in tap water to
remove crystal violet and left to air dry overnight. Once
dry, colonies were counted using a stereomicroscope to
determine plating efficiencies (PE) and survival fractions
(SF). PE = no. of colonies formed/no. of cells seeded ×
100 %. SF = no. of colonies formed after treatment/no. of
colonies seeded × PE. All experiments were carried out in
triplicate.
Wound healing migration assay
Cells were plated into individual round dishes (Corning)
and grown to 80–90 % confluency for 2–4 days in 5 %
CO2 in a humidified atmosphere at 37 °C in serum free
media. Once confluent, a “wound” was generated across
the cell lawn using a sterile blue tip after which media
was removed and replaced with media containing BAs.
Time zero dishes were prepared along with 24 h dishes
to assess closing of the wound relative to time. After this
period, dishes were fixed with 4 % formaldehyde in PBS
pH 7.4 for 15 min. Once fixed, dishes were washed in
PBS, stained with 0.2 % crystal violet for 10 min and
washed several times in distilled water. All dishes were
scored for migration distances on a stereomicroscope
and distances migrated between “wound” viewed and
captured on an Olympus BX-51.
Metabolic activity assay
DU-145 cells (untreated, DMOG treated and BAs +DMOG
treated cells) were assessed for metabolic activity using
the XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-
2H-Tetrazolium-5-Carboxanilide) assay at 24 h inter-
vals (over 4 days) in 96 well plates in 5 % CO2 in a
humidified atmosphere at 37 °C. Briefly, 100 μl freshly
prepared XTT (Sigma) and menandione was added to cells
in 96 well plates. After a 2 h incubation, cell metabolic
activity was determined by measuring the absorbance at
490 nm on a microplate spectrophotometer. All assays were
performed in triplicate.
Proliferation assay
DU-145 cells (untreated, DMOG treated and BAs +
DMOG treated cells) were seeded into 24 well plates
and assessed for proliferation over a 15 day period. For
staining, culture media was aspirated and cells fixed with
4 % paraformaldehyde at room temperature for 10 min.
Cells were then stained with 0.05 % crystal violet for
30 min after which cells were washed in water and air
dried on filter paper. Crystal violet dye was dissolved in
500 μl methanol and emission spectra measured at a
wavelength of 595 nm on a microplate spectrophotom-
eter. All assays were performed in triplicate.
Viability assay
DU-145 cells (untreated, DMOG treated and BAs +
DMOG treated cells) were assessed for cell viability
using trypan blue (live/dead) staining. Cells were seeded
into T25 flasks and assessed for cell viability every 24 h
over a 5 day period. On the day of assay, cells were gen-
tly scraped from the flask surface and 2 ml of PBS
added. The volume was mixed thoroughly (to remove
clumps) and centrifuged at 1200 rpm for 2 min to pellet
cells. The supernatant was decanted and the pellet sus-
pension mixed. Cells were removed and added to try-
pan blue and mixed (to remove clumps) thoroughly. An
aliquot was loaded onto a disposable chamber slide and
placed into the Countess™ Automated Cell Counter
(Invitrogen) to count live/dead cells (viability), repre-
sented as percentage cell viability. All assays were per-
formed in triplicate. Random counting of cells was also
carried out using a haemocytometer and inverted
microscope to assess the validity of Automated Cell
Counter data. All visual counts were within +/- 5 % of
Cell Counter data (data not shown).
Real-Time PCR
DU-145 cells (untreated, DMOG treated and BA +
DMOG treated) were collected in RNA Protect Cell Re-
agent (Qiagen, West Sussex, UK) and stored at −80 °C
until RNA extraction, using the RNeasy Minikit as per
the manufacturer’s instructions (Qiagen). DNase treat-
ment and reverse transcription were both performed
using the Quantitect Reverse Transcription kit (Qiagen).
Approximately 1 ug of RNA was reverse transcribed into
cDNA as per protocol. Quantitative RT-PCR was per-
formed using the FastStart Taqman probe master mix
(Roche) on a PTC-200 thermocycler (Bio-Rad) according
to manufacturer’s instructions. Primers were designed
using the Universal Probe Library Assay Design Centre
(Roche). HPRT-1 (Forward); gaccagtcaacaggggacat,
HPRT-1 (Reverse); gtgtcaattatatcttccacaatcaag (Probe 22).
HK II (Forward); tcccctgccaccagacta, HK II (Reverse);
tggacttgaatcccttggtc (Probe 54).
Statistical analysis
Three independent biological replicates (N = 3) were
performed for each experiment unless otherwise
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stated. Statistical significance was measured using a
paired two-tailed Student’s T-test. Differences were
considered to be statistically significant if the p-value
were; * P < 0.05; ** P < 0.01.
Results
Dihydroxylated BAs destabilise HIF-1α in A-549, MCF-7
and DU-145 cells
We previously demonstrated that BAs induced destabil-
isation of HIF-1α not only in IB3-1 and S-9 epithelial
cells but in A-549 lung adenocarcinoma cells [17].
Here, we assessed HIF-1α destabilisation in three
cancer cell lines using two independent methods;
immunofluorescence with an anti-HIF-1α antibody in
A-549, MCF-7 and DU-145 cells (Fig. 1a-c) and an
anti-HIF-1α subunit ELISA in DU-145 cells (Fig. 1d).
Untreated cells (normoxic conditions) were devoid of
green fluorescent punctae suggesting low HIF-1α levels
that would indicate rapid turnover of HIF-1α under
these conditions. DMOG treated (hypoxia mimetic con-
ditions) cells exhibited widespread HIF-1α punctate stain-
ing indicative of stabilised HIF-1α expression as expected.
In cells treated with DMOG plus either DCA or CDCA,
HIF-1α detection was faint and dispersed in DU-145 cells
(Fig. 1c), while in A-549 and MCF-7 cells (Fig. 1a and b),
no HIF-1α staining was observed. This suggests a reduc-
tion in HIF-1α expression and implicates BAs in HIF-1α
destabilisation. We also assessed HIF-1α quantitatively in
DU-145 cells using an anti-HIF-1α ELISA (Fig. 1d). As ex-
pected HIF-1α expression was increased in DMOG
treated cells compared to untreated controls. The pres-
ence of BAs reduced HIF-1α expression in DMOG treated
cells. This supports the conclusion that BAs generally pro-
mote HIF-1α destabilisation under hypoxic conditions.
Finally, we investigated the expression of hexokinase II
(HK II), a downstream transcriptional target of HIF-1α
(Fig. 1e). These data showed that HK II expression
increased in DMOG treated cells, whereas for both BAs,
Fig. 1 Dihydroxylated bile acids CDCA and DCA destabilise HIF-1α in A-549, MCF-7 and DU-145 cells. BAs destabilise HIF-1α in (a) A-549 cells, (b)
MCF-7 cells and (c) DU-145 cells. For fluorescent microscopy, all cells were grown under hypoxic conditions (DMOG 200 μM), except for untreated
cells. All cells were stained for intracellular HIF-1α (green) using an anti-HIF1α antibody and 4′, 6-diamidino-2-phenylindole (DAPI) for DNA nuclear
material (blue). HIF-1α staining was not observed in untreated cells whereas in DMOG treated cells, HIF-1α punctate staining was observed. Scale
bar = 20 μM, magnification × 63 oil immersion. HIF-1α was quantitatively assayed in DU-145 cells using an anti-HIF-1α ELISA in the presence of
BAs (d). Untreated cells exhibited reduced HIF-1α expression when compared to DMOG treated cells whereas in BA treated cells, HIF-1α levels
were lower. e. Hexokinase II RT-PCR. Expression data normalised to HPRT is the average of two biological replicates (with two technical replicates) and is
presented as fold change relative to the untreated control. Statistical analysis was performed using Repeated Measures ANOVA with post-hoc Bonferroni
testing (* p< 0.05). For other data, statistical significance was assessed via an unpaired, two-tailed Student t tests. *, P < 0.05. Data presented represent those
from three independent replicates
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HK II expression in DMOG treated cells was not statisti-
cally different to the untreated control.
Dihydroxylated BAs are not cytotoxic towards A-549, DU-
145 and MCF-7 cancer cells
Before assessing the impact of BAs on cancer cell phe-
notypes, it was important to establish whether or not
BAs exhibited cytotoxic activity towards these cells. The
effects of dihydroxylated BAs was assessed in all cell
lines using a lactate dehydrogenase (LDH) cytotoxicity
assay (Fig. 2a-c). Compared with exposure of cells to
0.1 % Triton X-100 that was assigned an arbitrary 100 %
LDH release value, untreated cells released minimal
LDH levels, reflective of uncompromised plasma mem-
branes and retained intracellular LDH. In the presence
of BAs, all cell lines released negligible (<10 %) LDH
reflecting the minimal impact of BAs on cytotoxicity at
this time-point.
We also assessed the impact of BAs on cell morph-
ology using simply phase contrast microscopy (shown
for DU-145 in Fig. 2d). This indicated no obvious differ-
ences between untreated and BA treated cells. Overall,
these assays indicated that minimal cytotoxic effects
were observed upon short-term exposure to BAs, which
is in the time frame in which motility and invasion as-
says can be performed.
BAs reduce DU-145 cell adhesive, migratory and invasive
potential
The DU-145 cell line was chosen as a cell model in
which to establish the impact of bile acids on cell pheno-
types associated with metastasis, including adhesion,
invasion and migratory capacity. DU-145 cells are
derived from an androgen-independent prostate cancer
and represents an aggressive cancer cell phenotype that
has undergone an Epithelial Mesenchymal Transition
Fig. 2 Dihydroxylated bile acids CDCA and DCA are not cytotoxic towards A-549, MCF-7 and DU-145 cells. For cytotoxicity assays, all cells were
grown under hypoxic conditions (DMOG 200 μM), except for untreated cells. Cells in the presence of 100 μM dihydroxylated BAs (CDCA and DCA)
were grown for 16 h and assessed for lactate dehydrogenase (LDH) production. Cytotoxicity was expressed as the mean percentage standard deviation
(SD) (n = 3) of the total LDH released from cells treated with 0.1 % Triton X-100, which was given an arbitrary value of 100 %. A-549 cells (a), MCF-7 cells
(b) and DU-145 cells (c) exhibited minimal cytotoxicity in the presence of BAs. DU-145 morphology in the presence of BAs was assessed by phase
contrast microscopy (d). Cells incubated with BAs exhibited cell shape and morphology similar to untreated cells. Data presented represent those from
three independent replicates. Student T-tests were performed for comparison of treated cells with control untreated cells (* P < 0.05)
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(EMT) that can be reversed by suppressing regulators of
EMT pathways in vitro [18].
We first established whether BAs triggered apoptosis
in DU-145 cells using FITC-labelled Annexin V to detect
exposed plasma membrane phosphatidylserine (PS) and
DAPI nuclear stain. Untreated control cells did not
present any PS staining (Fig. 3). In contrast, cells incu-
bated with the pro-apoptotic positive control [19], cinna-
binaric acid (150 μM) exhibited extensive PS staining
indicating extensive apoptosis induction. BA-treated
cells exhibited negligible green punctae indicating that
BAs do not induce apoptosis in DU-145 cells. This assay
combined with the cytotoxicity data (Fig. 2) demon-
strates that short term exposure to BAs has minimal
impact on cytotoxicity and apoptosis. Thus the effects of
BAs on cell adhesion, migration and invasion could be
further investigated without cell death confounding
assays.
The in vivo binding of cells to the extracellular matrix
(ECM) is essential for cell survival and cell-to-cell com-
munication, but is also essential for the metastatic
potential of cancer cells [20]. The effects of BAs on cell
adhesion were assessed in vitro by allowing DU-145 cells
to adhere to either collagen or Matrigel in the presence of
BAs and assessing the relative numbers of attached cells.
Untreated and DMOG-treated cells exhibited similar
adhesion to collagen (Fig. 4a) or Matrigel (Fig. 4b). Cells
treated with CDCA or DCA exhibited considerably re-
duced cell adhesion compared to controls (Fig. 4a and b).
This suggests that BAs reduce the ability of DU-145 cells
to adhere to ECMs which may impact on their migration
and invasion capacity.
The in vitro invasive and migratory capacity of metastatic
cancer cells provide insights into how cells behave in the
presence of modulators of cancer progression. Here, the in-
vasion capabilities of DU-145 cells in the presence of BAs
were assessed using Matrigel (on 0.8 μm membranes)
(Fig. 5a) and directional migration was assessed using
Transwell assays (Fig. 5b). DU-145 cell invasion and migra-
tion were both reduced approximately 2-fold compared to
untreated control cells. This indicates that BAs impair the
ability of these cells to invade and migrate efficiently.
To further explore migratory potential, a wound heal-
ing assay was performed (Fig. 6). One of the advantages
of this assay is that it mimics the migration of wounded
cells in vivo [21]. Untreated DU-145 monolayers were
wounded at 0 h, fixed, stained and photographed to
establish a basal reference wound. Treated cells were
then allowed to fill the wound and at 24 h were similarly
stained and photographed to assess cell migration rela-
tive to both time and the presence of BAs. Compared to
the time 0 h reference wound (Fig. 6) both untreated
and DMOG treated cells displayed extensive wound clo-
sures after 24 h, reflective of similar cell migratory pat-
terns. Cells exposed to BAs exhibited slightly reduced
wound healing patterns at 24 h for both CDCA and
DCA respectively. These data demonstrate BAs impaired
DU-145 cell migratory potential.
The clonogenic potential of DU-145 and MCF-7 cells is
significantly reduced in the presence of BAs
To investigate the long-term effects of exposure of can-
cer cells to BAs, we used clonogenic assays which meas-
ure a key cancer cell phenotype; the ability to form
colonies when seeded at low density. The clonogenic
potential of A-549, MCF-7 and DU-145 cells was
assessed in the presence of BAs over a twenty one day
period (Fig. 7a-c). The cell survival fraction (an index of
clonogenic growth and cell survivability) was reduced
for MCF-7 and DU-145 cells (Fig. 7b and c) but was
unaltered for A-549 cells (Fig. 7a). For all cell lines
tested, untreated and DMOG-treated cells were charac-
terised by high colony density (no measurable differences).
Similarly, BAs had no effect on A-549 clonogenicity as
Fig. 3 Dihydroxylated BAs do not induce apoptosis in DU-145 cells. For apoptosis assays, all cells were grown under hypoxic conditions
(DMOG 200 μM), except for untreated cells. DU-145 cells in the presence of 100 μM dihydroxylated BAs (CDCA and DCA) were grown for
16 h and stained with 4′,6-diamidino-2-phenylindole (DAPI) for deoxyribonucleic acid (DNA) (blue) and Annexin V AlexaFluor 488 fluorescence (green).
Supplementation of the red pigmented phenoxazinone, cinnabarinic acid (150 μM) to cells acted as positive control. Untreated cells and cells treated
with BAs displayed no green fluorescent punctae, whereas positive control cells exhibited green fluorescent punctae indicative of apoptosis at the
membrane. Fluorescent microscopy data represent those from one of three independent experiments. Between 10 and 15 images were recorded for
each condition. Scale bar = 20 μM. Magnification × 63
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evidenced by dense staining in all plates, high colony
numbers and no measurable differences. However, BA-
treated DU-145 and MCF-7 cells exhibited greatly
reduced colony numbers. These data demonstrate that
BAs markedly inhibited the clonogenic and survival
potential of DU-145 and MCF-7 cells. This suggests that
exposure to BAs would limit the survival and metastatic
potential of cancer cells under conditions of hypoxia.
Importantly, in DU-145 cells, the reduction in colony for-
mation numbers was independent of metabolic activity,
Fig. 4 DU-145 adhesion to collagen and matrigel in the presence of dihydroxylated BAs is reduced. For adhesion assays, all cells were grown
under hypoxic conditions (DMOG 200 μM), except for untreated cells. DU-145 cells in the presence of 100 μM dihydroxylated BAs were seeded into 96 well
plates coated with collagen and matrigel and allowed adhere for 24 h after which supernatants were removed and adhered cells washed and stained with
crystal violet. Plates were assayed on a plate reader at 550 nm. All data were derived from three independent experiments, N= 3, S.D; * P< 0.05; ** P< 0.01
Fig. 5 Dihydroxylated BAs impair invasion and migration of DU-145 cells. For invasion and migration assays, all cells were grown under hypoxic
conditions (DMOG 200 μM), except for untreated cells. Boyden chambers alone (migration) and those containing Matrigel (invasion) were hydrated for
at least 2 h with 500 μl serum free media in the bottom of the well and 500 μl serum free media in the chamber. Once hydrated, the media in the
bottom was replaced with media supplemented with 10 % FCS and the media in the chamber was replaced with cells in media supplemented with
10 % FCS. After growing for 24 h at 5 % CO2 in a humidified atmosphere at 37 °C, cells were fixed, rinsed, dried and counted. Cell migration and
invasion data were derived from three independent experiments, N = 3, S.D; * P < 0.05; ** P < 0.01
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cell proliferation and cell viability, which all remained rela-
tively unchanged over time of exposure to BAs (Fig. 8a–c).
Discussion and conclusions
The main characteristics of cancer cell progression are
abnormal cell growth and proliferation followed by rapid
migration, invasion, adhesion and the formation of tu-
mours at new sites [22]. Concomitant to external pheno-
typic changes, many epigenetic changes occur within the
tumour environment, most notably in hypoxic tumours
where HIF-1 (full length) activation in combination with
reduced oxygen and down-stream effector activation,
Fig. 6 Dihydroxylated BAs impair scratch-wound healing in DU-145 cells. For scratch-wound healing assays, all cells were grown under hypoxic
conditions (DMOG 200 μM), except for untreated cells. Monolayer cells were grown until 80 % confluent, wounded, stained and images recorded after
wounding at 0 and 24 h. Distances between scratch-wound fronts were measured using a steromicroscope and were represented as μm. At least 20
measurement points were taken per condition and averaged data were derived from three independent experiments, N = 3, S.D; * P < 0.05; ** P < 0.01
Fig. 7 Dihydroxylated bile acids CDCA and DCA affect the clonogenic ability and cell survival of MCF-7 and DU-145 cells. For clonogenic assays,
all cells were grown under hypoxic conditions (DMOG 200 μM), except for untreated cells. A-549 cells (a), MCF-7 cells (b) and DU-145 cells (c) in the
presence of 100 μM BAs cells were seeded into 6 well plates and grown over a twenty one day period. Resulting colonies were washed, stained with
0.5 % crystal violet and counted using a steromicroscope. To calculate the surviving fraction (SF), the plating efficiency (PE) was calculated; PE = number
of colonies formed/no. of cells seeded × 100 %. This value was used to determine the SF; number of colonies formed after treatment/no. of cells
seeded × PE. Clongenic data were derived from three independent experiments, N = 3, S.D; * P < 0.05; ** P < 0.01
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contribute to a tumour microenvironment that favours
phenotypic changes necessary for metastasis [14]. We
demonstrated HIF-1α destabilisation in A-549, MCF-7
and DU-145 cells, reinforcing the premise that expres-
sion of this key transcription factor can be regulated by
CDCA and DCA and suggests a novel BA/HIF-1α inter-
play during cancer progression.
BAs were not cytotoxic towards these cells, suggesting
this destabilisation phenotype was influenced by the
presence of BAs. HIF-1α subunit expression and stabil-
isation is a common phenomenon observed in many
hypoxic tumours, therefore its strategic targeting and
destabilisation is of critical value from a clinical and
survival perspective [14, 23, 24]. The HIF-1α subunit
may be targeted at the transcriptional, translational and
post-translational levels which has allowed development
of agents that destabilise or block HIF-1α activation
[25]. Many chemical and molecular inhibitors have been
developed to destabilise HIF-1α [26–28], however, many
have not progressed to clinical trials due to non-
specificity and cytotoxicity issues [29]. Our data suggests
that BAs could provide an innate protection against hyp-
oxic tumour development and circumvent specificity
and cytotoxicity issues. Beneficial BAs could be supplied
via the diet or from specific pools of BAs derived from
ingestion of bile producing bacteria.
Not only was a HIF-1α destabilisation phenotype
observed in all cancer cells tested, but BAs greatly
reduced the clonogenic potential of DU-145 and MCF-7
cells. Specifically for DU-145 cells, clonogenicity was in-
dependent of metabolic activity, cell proliferation and
cell viability, suggesting BAs targeted the cells repro-
ductive ability to form progenies. Furthermore the adhe-
sive, migratory and invasive capacity of DU-145 cells
were consistently decreased by BAs. Taken together,
with the decreased clonogenic growth, these data indi-
cate that BAs can reverse key phenotypes associated
with metastatic cancer cells, particularly in the context
of hypoxia and HIF-1α destabilisation. The loss of hall-
mark cancer phenotypes has been reported in associ-
ation with HIF-1α knock-down/destabilisation in several
cell types (gastric cancer cells, pancreatic cancer cells
and uveal melanoma cells [30–32]. While these reports
implicate the HIF-1α subunit in cancer progression asso-
ciated phenotypes, its precise mechanistic role in con-
junction with BAs remains to be elucidated. However,
expression of HK II, a cellular glycolytic enzyme and a
transcriptional target of HIF-1α, was affected by BAs,
demonstrating possible downstream perturbations of the
HIF-1α network.
In terms of cancer progression, previous studies have
shown dramatic effects of BAs on cancer progression in
different cell models (stomach, duodenum, oesophagus
and colon cancers) [33–37]. Animal models and in vitro
cell assays using BAs at supra-physiological concentra-
tions have been cited as causative agents in the gener-
ation of cancerous lesions at these sites. Prolonged
exposure to BAs (e.g. stomach, colon and oesophagus)
promote an in situ hyperplasic dysmorphia (cell elong-
ation, proliferation and polarisation), and over time, cells
become neoplastic leading to tumour development.
While the molecular links between BA metabolism and
cancer are not fully elucidated, definitive roles for BAs
in cancer progression cannot be overlooked in view of
the evidence presented in this study.
Modulation of BA intake, primarily via the diet, could
exert protective effects on the spread of hypoxic cancer-
ous lesions at several sites within the body (e.g. breast
Fig. 8 Dihydroxylated bile acids CDCA and DCA do not affect the metabolic activity, proliferation and cell viability of DU-145 cells. For metabolic
activity (XTT), proliferation (crystal violet) and cell viability (trypan blue) assays, all cells were grown under hypoxic conditions (DMOG 200 μM),
except for untreated cells. For all assays, no significant compromises were observed in cell metabolic activity, cell proliferation and cell viability
with respect to time. All data were derived from three independent experiments
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and prostate) (Fig. 9). Concerted efforts to establish
long-term effects of probiotics/prebiotics on dysbiosis
have been proposed, however cause and effect relation-
ships have not been established for such interventionist
approaches [11, 12]. Similarly, diets high in fat, sugar
and meat perturb the gut microbiota balance leading to
increased risks of e.g. colorectal cancer [38]. Evidence
suggests a more Mediterranean approach to diet (fruits
and vegetables, whole grains, legumes and nuts, olive
oil, herbs and spices, limited red meat, fish and poultry
and red wine (optional) in moderation) exerts a “prob-
able” long term protective role against cancer. However
more empirical data is required, along with well
designed, randomised, longitudinal studies to support
these observations [39].
Bile acids exert dramatic effects on cancer development
and progression. Several cancer phenotypes were signifi-
cantly affected in the presence of BAs suggesting these
molecules are not only important for lipid metabolism,
but are potential mediators of cancer progression. Future
research in this area requires extensive phenotypic charac-
terisation of the role of BAs in other cancer models, in-
depth molecular investigations of HIF-1α effectors and
their specific roles in invasion, migration, adhesion and
cell survival.
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